Analysis of drug resistance of klebsiella pneumoniae in 61 patients with bloodstream infection

Objective To understand the distribution and drug resistance of klebsiella pneumoniae in patients with bloodstream infection in a hospital in Foshan, and to guide the rational use of antibiotics in clinical practice. Methods The distribution and drug resistance of klebsiella pneumoniae in hospitalized patients with bloodstream infection from January 1, 2015 to December 31, 2017 were retrospectively investigated. The klebsiella pneumoniae was cultured and isolated by conventional methods, and the drug sensitivity test was conducted by K-B method. The results were interpret according to the latest CLSI standard. Results 61 strains of klebsiella pneumoniae were detected, mainly from tumor hematopathy and ICU, accounting for 21.3% and 19.7%, respectively. More than 95% of klebsiella pneumoniae were resistant to ampicillin, but were sensitive to meropenem, imipenem, and amikacin. The detection rate of ESBLs producing strains was 25.4% (15/61), and whose drug resistance rate was significantly higher than that of non-ESBLs producing strains. Only 3 cases of carbapenem-resistant strains were detected in 2017, which were sensitive to tigecycline and polymyxin. Conclusion The drug resistance of klebsiella pneumoniae isolated from bloodstream infection is serious, and the strains producing ESBLs and carbapenem-resistant are increasing. Clinicians should apply antibiotics reasonably to improve the clinical treatment effect. Key words: Bloodstream infection; Klebsiella pneumoniae; Drug resistance analysis